ArticleJournal for immunotherapy of cancer2025
Biomimetic carbon nanopolymers ANM-NPs act on mannose receptors and complement receptors to promote tumor antigen presentation.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhancing immunogenicity and antigen-presentation efficiency is critical for tumor vaccine development. While yeast-surface glycoprotein side chains can improve antigen presentation, their ability to deliver tumor antigens remains limited.
methodsThe composite carbon nanopolymers (Asparagine-N-acetylglucosamine-Mannose derived carbon nanopolymers, ANM-NPs) mimicking yeast-surface glycans side chains were prepared using asparagine, N-acetylglucosamine and mannose as precursors via microwave-assisted synthesis method. Combined with whole-cell tumor antigen (T-Ag), the vaccine ANM-NPs@T-Ag was prepared. The expression levels of major histocompatibility complex-II, CD80, and CD86 were analyzed by flow cytometry to evaluate the enhancement of antigen presentation. The antitumor efficacy of ANM-NPs@T-Ag was assessed by H22-LUC and B16-F10-LUC tumor-bearing models.
resultsANM-NPs have an average particle size of approximately 21.69 nm and exhibit good stability. Compared with traditional aluminum adjuvants, ANM-NPs demonstrate superior efficacy in promoting antigen presentation and immune activation. ANM-NPs effectively stimulated innate immunity, facilitated immune cell infiltration, and enhanced adaptive immune responses. The vaccine ANM-NPs@T-Ag targeted dendritic cells via mannose receptors, activating the lectin pathway, improving complement opsonization, and enhancing antigen presentation. ANM-NPs@T-Ag stimulated cellular/humoral immunity, increased tumor-specific IgG, and inhibited tumor growth. ANM-NPs@T-Ag also enhanced the antitumor effect of α-PD-1 (programmed cell death protein-1).
conclusionThese findings demonstrate that ANM-NPs can serve as a potential vaccine adjuvant, and ANM-NPs@T-Ag represents a promising tumor vaccine candidate.Cite Now.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.